Cargando…

Survival analysis of bevacizumab plus taxane treatment in luminal metastatic breast cancer

BACKGROUND: The treatment of luminal metastatic breast cancer is based on endocrine therapy and chemotherapy treatment is limited to the progression of this treatment. MATERIALS & METHODS: We analyzed the efficacy of treatment with bevacizumab plus paclitaxel in 43 patients with hormone receptor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Murillo, Serafin Morales, Cudos, Ariadna Gasol, Rodriguez, Joel Veas, Morales, Carles Canosa, Olivé, Jordi Melé, Villellas, Felip Vilardell, Sanchez Guzman, Douglas Rene, Martínez, Edelmiro Iglesias, Salvia, Antonieta Salud
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Science Ltd 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849928/ https://www.ncbi.nlm.nih.gov/pubmed/33552547 http://dx.doi.org/10.2144/fsoa-2020-0146

Ejemplares similares

Selection of neoadjuvant treatment based on the 21-GENE test results in luminal breast cancer
por: Morales Murillo, Serafin, et al.
Publicado: (2021)

Her2-Positive Cancers and Antibody-Based Treatment: State of the Art and Future Developments
por: Morales, Serafin, et al.
Publicado: (2021)

Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial
por: Quintela-Fandino, Miguel, et al.
Publicado: (2020)

Importance of assessing CK19 immunostaining in core biopsies in patients subjected to sentinel node study by OSNA
por: Vilardell, Felip, et al.
Publicado: (2012)

Human Menstrual Blood-Derived Mesenchymal Stem Cells as Potential Cell Carriers for Oncolytic Adenovirus
por: Moreno, R., et al.
Publicado: (2017)

Are Transcription Factors Plausible Oncotargets for Triple Negative Breast Cancers?
por: Marqués, Marta, et al.
Publicado: (2022)

Applications of CRISPR Technology to Breast Cancer and Triple Negative Breast Cancer Research
por: Pont, Mariona, et al.
Publicado: (2023)

Low-dose-intensity bevacizumab with weekly irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer
por: Liu, Ying, et al.
Publicado: (2015)

A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer
por: Loupakis, Fotios, et al.
Publicado: (2015)

Adjuvant therapy of endometrial cancer: “taxane or not taxane, this is the question”
por: Lorusso, Vito, et al.
Publicado: (2019)

Cryotherapy after Topical Interferon Alpha 2b to Treat Conjunctival Primary Acquired Melanosis
por: Huerva, Valentín, et al.
Publicado: (2023)

FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ-1 trial
por: Aranda, Enrique, et al.
Publicado: (2020)

P-gp and taxanes
por: Hendrikx, Jeroen J.M.A., et al.
Publicado: (2014)

Mechanisms of Taxane Resistance
por: Maloney, Sara M., et al.
Publicado: (2020)

Combination Chemotherapy of Mitomycin C and Methotrexate Was Effective on Metastatic Breast Cancer Resistant to Eribulin, Vinorelbine, and Bevacizumab after Anthracycline, Taxane, and Capecitabine
por: Tanabe, Masahiko
Publicado: (2016)

Taxane-induced acute interstitial pneumonitis in patients with breast cancer and outcome of taxane rechallenge
por: Anoop, T M, et al.
Publicado: (2022)

Neoadjuvant chemotherapy outcome with taxane-based versus non-taxane protocols in gastric cancer
por: Kianersi, Shirin, et al.
Publicado: (2023)

Taxane-Induced Peripheral Neurotoxicity
por: Velasco, Roser, et al.
Publicado: (2015)

Sex Differences in Taxane Toxicities
por: Chmielewski, Nicole N., et al.
Publicado: (2022)

Correlation of Hypertension and Proteinuria with Outcome in Elderly Bevacizumab-Treated Patients with Metastatic Colorectal Cancer
por: Feliu, Jaime, et al.
Publicado: (2015)

Acral reed nevus with parallel ridge pattern: an exception to the rule of malignancy()
por: Canal-Garcia, Elena, et al.
Publicado: (2023)

Conventional and digital Ki67 evaluation and their correlation with molecular prognosis and morphological parameters in luminal breast cancer
por: Pons, Laura, et al.
Publicado: (2022)

Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study
por: Garcia-Alfonso, Pilar, et al.
Publicado: (2015)

Bevacizumab Combined with Platinum–Taxane Chemotherapy as First-Line Treatment for Advanced Ovarian Cancer: Results of the NOGGO Non-Interventional Study (OTILIA) in 824 Patients
por: Sehouli, Jalid, et al.
Publicado: (2021)

Raloxifene and Bevacizumab for severe complications of hereditary haemorrhagic telangiectasia in a haemodialysis patient
por: Morales, Enrique, et al.
Publicado: (2012)

Docetaxel: an alternative taxane in ovarian cancer
por: Katsumata, N
Publicado: (2003)

Disposition Kinetics of Taxanes in Peritoneal Dissemination
por: Miyamoto, Ken'ichi, et al.
Publicado: (2012)

Scalable, enantioselective taxane total synthesis
por: Mendoza, Abraham, et al.
Publicado: (2011)

Taxanes for the Treatment of Metastatic Breast Cancer
por: Gradishar, W.J.
Publicado: (2012)

Taxanes in the Treatment of Advanced Gastric Cancer
por: Kang, Byung Woog, et al.
Publicado: (2016)

Impact of taxanes on androgen receptor signaling
por: Bai, Shanshan, et al.
Publicado: (2019)

Taxane-Induced Upper Gastrointestinal Bleeding
por: Liu, Yao, et al.
Publicado: (2021)

Hypersensitivity Reactions to Platinum Agents and Taxanes
por: Tsao, Lulu R., et al.
Publicado: (2021)

Structural insight into the stabilization of microtubules by taxanes
por: Prota, Andrea E, et al.
Publicado: (2023)

A Prospective Study of Taxane-Induced Neuropathy with Breast Cancer: Proper Assessment Tool for Taxane-Induced Neuropathy
por: Sohn, Eun Hee, et al.
Publicado: (2021)

THE TOTAL LUMINOUS EFFICIENCY OF LUMINOUS BACTERIA
por: Harvey, E. Newton
Publicado: (1925)

Upfront Taxane Could Be Superior to Pegylated Liposomal Doxorubicin (PLD): A Retrospective Real-World Analysis of Treatment Sequence Taxane–PLD versus PLD–Taxane in Patients with Metastatic Breast Cancer
por: Wallrabenstein, Till, et al.
Publicado: (2023)

Cálculo de estructuras de acero / Vicente Cudós Samblancat
por: Cudos,Vicente
Publicado: (1978)

Optimal use of taxanes in metastatic breast cancer
por: King, K.M., et al.
Publicado: (2009)

New Taxane Diterpenoids from Taxus yunnanensis
por: Hai, Ping, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_p25k3jes7jd3i91a6mheei730l